Mobile

The trial is designed to determine the efficacy and safety of ABP 980 compared with Trastuzumab in subjects with HER2 positive early breast cancer

Mise à jour : Il y a 4 ans
Référence : EUCTR2012-004319-29

Femme Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To compare the treatment effect of ABP 980 with trastuzumab on pathologic complete response (pCR) in women with early breast cancer

Critère d'inclusion

  • HER2-positive early breast cancer

Liens